Pharmacological Characterization Of 1-(5-Chloro-6-(Trifluoromethoxy)-1h-Benzoimidazol-2-Yl)-1h-Pyrazole-4-Ca Rboxylic Acid (Jnj-42041935), A Potent And Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

The hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzymes represent novel targets for the treatment of anemia, ulcerative colitis, and ischemic and metabolic disease inter alia. We have identified a novel small-molecule inhibitor of PHD, 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-mpyrazole-4-carboxylic acid (JNJ-42041935), through structurebased drug design methods. The pharmacology of JNJ42041935 was investigated in enzyme, cellular, and wholeanimal systems and was compared with other compounds described in the literature as PHD inhibitors. JNJ-42041935, was a potent (pK(I) = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes. In addition, JNJ-42041935 was used to compare the effect of selective inhibition of PHD to intermittent, high doses (50 mu g/kg i.p.) of an exogenous erythropoietin receptor agonist in an inflammation-induced anemia model in rats. JNJ-42041935 (100 mu mol/kg, once a day for 14 days) was effective in reversing inflammation-induced anemia, whereas erythropoietin had no effect. The results demonstrate that JNJ-42041935 is a new pharmacological tool, which can be used to investigate PHD inhibition and demonstrate that PHD inhibitors offer great promise for the treatment of inflammation-induced anemia.